Central Nervous System Attention Deficit Disorder with Hyperactivity

Table of Contents

RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Attention Deficit Disorder with Hyperactivity Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects

--Top Companies in late stage Attention Deficit Disorder with Hyperactivity Projects
--Abbott Laboratories
--Addrenex Pharmaceuticals, Inc.
--CoMentis, Inc.
--Cortex Pharmaceuticals Inc
--Impax Laboratories Inc
--Merck & Co Inc
--NeuroSearch A/S
--Pfizer Inc
--Saegis Pharmaceuticals, Inc.
--Sciele Pharma, Inc.
--Shire plc

--Top Companies in early stage Attention Deficit Disorder with Hyperactivity Projects
--Dnaprint Genomics Inc
--Dov Pharmaceutical Inc
--Eli Lilly & Co
--ICAgen Inc
--Mitsubishi Tanabe Pharma Corporation
--Noven Pharmaceuticals Inc
--Omeros Corporation
--Phase 2 Discovery, Inc.
--Sanofi-Aventis
--Shire plc
--Sosei Group Corporation

Pipeline Revenue
--Pipeline Revenue
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--Pending Approval Pipeline View
--Approved Pipeline View
--Post Marketing Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View